Recurrence Clinical Trial
Official title:
Diagnostic Accuracy of Positron Emission Tomography/ Computed Tomography With 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients With Colorectal Cancer
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading
cause of cancer death in the United States.
The overall relative 5-year survival is about 50%-60% but is highly dependent on disease
stage at the time of diagnosis ranging from approximately 80% to only 3%.
Curative treatment comprises resection of the primary tumour combined with adjuvant
chemotherapy in selected patients. In recent years there has been an increasing role for
curative intended surgical or ablative intervention in limited metastatic disease, i.e.,
solitary or few metastases to the liver and/or the lungs. Accurate preoperative staging is of
paramount importance for directing the most appropriate therapeutic options, for indicating
prognosis and outcome, and to avoid futile operations.
The use of imaging in the staging and restaging of colorectal cancers has been evolving and
improving in the last two decades. Magnetic resonance imaging (MRI) is an accepted modality
for staging of rectal cancer, allowing an accurate identification of transmural invasion of
the mesorectal fat and mesorectal fascia involvement. Computed tomography (CT) significantly
lacks resolution of soft tissue contrast so that its utility in T staging of rectal cancer is
limited. Due to the higher sensitivity and specificity compared with CT,Positron Emission
Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (FDG PET/CT) is recommended
for use in a metastatic patients.
Pelvic MRI and 18F-FDG PET/CT are useful for staging and therapeutic management. Pelvic MRI
allows for accurate definition of the distance to mesorectal fascia which is a predictor of
the local recurrence rate, as well as for definition of the regional nodal status. 18F-FDG
PET/CT also helps in evaluating the nodal status and is especially performed for the
detection of distant metastases. MRI and 18F-FDG PET/CT are thus 2 complementary modalities
for the initial staging of advanced rectal cancer.
Neoadjuvant therapies are performed for stage II and stage III rectal cancer. It has been
shown that neoadjuvant therapy decreases local recurrence and increases survival. Therefore,
correct preoperative staging has a critical role in determining whether patients should
undergo neoadjuvant therapy.
The literature on the clinical use of FDG-PET/CT in colorectal cancer staging is fairly
limited, but recent works have demonstrated some promise for optimizing the accuracy of
initial staging by clarifying equivocal findings on conventional imaging in preoperative
staging, and evaluating apparently limited metastatic disease before intervention .
It was reported that the use of FDG-PET/CT in this study changed the planned treatment
strategy in a total of 30% of the patients. A change from palliative to curative or vice
versa was seen in almost 10% of the patients.
PET/CT provides high accuracy for the detection and staging of liver lesions in CRC patients,
PET led to a change in patient management in an average of 24 % of patients, including both
exclusion from curative surgery and modification of the surgical approach.
Risk of local recurrence is substantial and correlates to the extension and grade of the
tumor and to the nodal status at initial presentation. The guidelines also highlight the
usefulness of PET/CT for restaging in the setting of a serially elevated carcinoembryonic
antigen level (CEA), negative results on conventional imaging, and potentially resectable
metachronous metastases documented by CT, MRI, or biopsy.It was reported that a high
sensitivity and specificity of 18F-FDG PET/CT in detecting recurrent CRC, largely regardless
of CEA levels, as well as they concluded that 18F-FDG PET/CT have high diagnostic value and
can be used as the first choice in the detection of recurrent CRC in patients with
unexplained rising CEA, even in patients with a recent normal routine CT.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03545659 -
Childhood Acute Lymphoblastic Leukaemia: Follow-Up
|
||
Completed |
NCT04838613 -
Study of Diagnostic Performance of [18F]CTT1057 in BCR
|
Phase 3 | |
Recruiting |
NCT05233020 -
Robotic Versus Hybrid Assisted Ventral Hernia Repair
|
N/A | |
Recruiting |
NCT04266600 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease
|
N/A | |
Recruiting |
NCT04539665 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.
|
N/A | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT01141335 -
Polypropylene Mesh Versus Polytetrafluoroethylene (PTFE) Mesh in Inguinal Hernia Repair
|
Phase 4 | |
Completed |
NCT00029185 -
Study of Dehydrex in Patients With Corneal Erosion
|
N/A | |
Completed |
NCT01351974 -
Sentinel Node Biopsy in Breast Cancer Patients
|
N/A | |
Not yet recruiting |
NCT06038422 -
GTP Regimen in the Treatment of Refractory/Recurrent HLH
|
Phase 3 | |
Withdrawn |
NCT03162120 -
Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
|
Phase 2/Phase 3 | |
Recruiting |
NCT04159051 -
Charité HT-Prostate
|
N/A | |
Recruiting |
NCT02566928 -
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence
|
Phase 4 | |
Completed |
NCT01989845 -
Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
|
Phase 4 | |
Recruiting |
NCT01229475 -
Stepwise Approach Versus Linear Ablation in Patients With Recurrence of Persistent Atrial Fibrillation
|
N/A | |
Completed |
NCT00944554 -
Relapse Prevention With Varenicline
|
Phase 4 | |
Terminated |
NCT02247258 -
Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.
|
Phase 2 | |
Completed |
NCT03654209 -
Post-resection Treatment of Large Colon Polyps
|
N/A | |
Recruiting |
NCT05557474 -
Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit
|
||
Active, not recruiting |
NCT03865537 -
Cold Snare Endoscopic Mucosal Resection Trial
|
N/A |